WuXi STA, a China-based Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Tuesday the ground-breaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.

The company said that the site will be its second facility in the United States, providing expanded capacity and greater flexibility to meet the requirements of customers in the United States and around the world.

The facility is to create around 500 full-time jobs by 2026. Phase one of the new campus is to provide formulation development, clinical and commercial drug product manufacturing services for various oral and injectable dosage forms and packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.

The facility is likely to commence operations in 2025.